Navigation Links
BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA
Date:7/15/2009

PRINCETON, N.J., July 15 /PRNewswire/ -- BioWa, Inc. announced today that it has entered into a license agreement with Merck KGaA, Darmstadt, Germany, providing the global healthcare and chemicals company with access to BioWa's POTELLIGENT((R)) Technology platform for the research, development and commercialization of their antibody therapies with enhanced antibody-dependent cellular cytotoxicity (ADCC).

"We are extremely pleased about our partnership with Merck KGaA, a global healthcare company with a strong worldwide presence," commented Dr. Masamichi Koike, BioWa's President and CEO. "Merck KGaA's world-class R&D organization and global market presence will enable us to promote and extend the benefit of the technology to patients all over the world more efficiently."

Under the terms of the license agreement, BioWa grants Merck KGaA non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through POTELLIGENT((R)) Technology for an undisclosed number of targets. In return, BioWa will receive upfront payments, and may receive development milestone payments and royalties on products. Other details of the agreement are not disclosed.

About POTELLIGENT((R)) Technology

POTELLIGENT((R)) Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT((R)) Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT((R)) Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. A number of POTELLIGENT((R)) antibodies are being investigated in human clini
'/>"/>

SOURCE BioWa, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
2. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
3. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
4. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
5. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
6. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014   Sequenom, Inc. ... company that provides innovative genetic analysis solutions, and ... esoteric laboratory services in the United States ... prenatal testing patents and applications. "We have ... and patient care, and we welcome the opportunity to ...
(Date:7/29/2014)... separated from its properties? On July 29, the prestigious ... the first Cheshire Cat experiment, separating a neutron from ... CA, and Vienna University of Technology. , Chesire Cat"Well! ... Alice in Wonderland, "but a grin without a cat! ... my life!" Alice,s surprise stems from her experience that ...
(Date:7/29/2014)... created a new way of manufacturing microstructured surfaces ... by self-assembly of carbon nanotubes, could exhibit a ... stiffness and strength, or the ability to repel ... demonstrated that mechanical forces can be used to ... that we can independently control the mechanical ...
(Date:7/29/2014)... 2014  Pomerantz LLP is investigating claims on behalf ... "Company") (NASDAQ: IPXL).  Such investors are advised to contact ... or 888-476-6529, ext. 237. The investigation concerns ... have violated Sections 10(b) and 20(a) of the Securities ... 29, 2014, Impax Laboratories, Inc. (the "Company") issued a ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4A new way to make microstructured surfaces 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2
... 30 VEGA PROMOTIONAL SYSTEMS, INC. (Pink Sheets: VGPR) today ... Power Company, Inc. to assist the Company in building a ... Vega recently announced its intention to build a biomass plant ... materials in the State,s Bioenergy Corridor. Georgia ranks third ...
... Novavax, Inc. (Nasdaq: NVAX ) announced today ... (VLP) vaccine technology to ROVI Pharmaceuticals (Madrid: ROVI) of ... create a comprehensive influenza vaccine solution for the Spanish ... led by the Spanish Ministry of Health and other ...
... Bion Environmental Technologies, Inc. (OTC Bulletin Board: BNET) ... Patent application 11/592,513 entitled "Low Oxygen Biologically Mediated Nutrient ... on November 6, 2006; upon publication and issuance, the ... force until November 5, 2024. This new patent strengthens ...
Cached Biology Technology:Vega Picks Tennessee Firm to Assist with Construction of Biomass Plant in Georgia 2Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 2Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 3Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 4Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 5Bion Announces Approval of New U.S. Patent that Broadens Protection for the Company's Livestock Waste Environmental Treatment Processes 2
(Date:7/29/2014)... wrong food at a restaurant, don,t blame yourself; blame the ... with what you want and more to do with a ... the selections of over 300 diners, the Cornell study published ... showed that when it comes to what you order ... the menu and how you imagine it will taste. , ...
(Date:7/29/2014)... debilitating effects of a stroke is an immensely ... as well as effective therapy. Advancing such knowledge ... the primary focus of research by Sergei Adamovich, ... the NJIT faculty more than a decade ago. ... substantial funding from sources such as the National ...
(Date:7/29/2014)... developed an easier method to create DNAprotein conjugates. ... in diagnosing diseases. , DNA linked to proteins ... that can be used in diagnostic techniques, nanotechnology ... proteins with DNA can be used for ... of biological material. The method also provides easier ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3New method provides researchers with efficient tool for tagging proteins 2
... February 20, 2012A team of researchers has found a ... will continue to be available, despite the potential attack ... Disease and poses a significant threat to the California ... Alamos National Laboratory (LANL), University of California at Davis ...
... PA, February 21, 2012 Using a noninvasive test on ... new algorithm for analysis, scientists can detect, with a high ... chromosomal abnormalities that cause Down syndrome and a genetic disorder ... scalable than other recently developed genetic screening tests and has ...
... has awarded The University of Texas at Austin and ... Dynamics Collaboratory (DDC), a network of researchers working to ... reliably predict the physical and ecological evolution of river ... the project, including Paola Passalacqua, assistant professor in Civil, ...
Cached Biology News:More grapes, less wrath: Hybrid antimicrobial protein protects grapevines from pathogen 2Noninvasive method accurately and efficiently detects risk of Down syndrome 2Noninvasive method accurately and efficiently detects risk of Down syndrome 3Engineering, geoscience faculty help lead $3 million NSF Delta research collaboration 2
... The HEEBO (Human Exonic Evidence Based ... Evidence Based Oligonucleotide ) Genome Set contain ... largely derived from constitutively expressed exons, allowing ... collaboration with leading researchers at Stanford University ...
odz, odd Oz/ten-m homolog 1 [Source:RefSeq_peptide;Acc:NP_055068] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
Biology Products: